Alembic Limited
NSE: ALEMBICLTD BSE: ALEMBICLTD
NSE
119.81
0.42 (0.35%)
Prev Close
119.39
Open Price
119
Volume
372,813
Today Low / High
118.76 / 121.33
52 WK Low / High
85.46 / 169
Range
114 - 126
BSE
119.60
0.15 (0.13%)
Prev Close
119.45
Open Price
120.85
Volume
41,860
Today Low / High
118.75 / 121.45
52 WK Low / High
85.55 / 169
Range
114 - 126
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 119.81 (target range: 114 - 126), reflecting a change of 0.42 (0.35179%). On the BSE, it is listed at 119.6 (target range: 114 - 126), showing a change of 0.15 (0.12558%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
03 Jul
121.00
-1.33%
02 Jul
122.60
-1.24%
01 Jul
124.70
-1.34%
30 Jun
117.00
4.10%
27 Jun
114.80
0.44%
26 Jun
116.00
-1.09%
25 Jun
112.97
1.90%
24 Jun
112.00
0.14%
23 Jun
109.10
1.25%
20 Jun
110.64
0.55%
19 Jun
115.70
-4.50%
18 Jun
116.17
-1.41%
17 Jun
114.90
1.11%
16 Jun
115.79
-0.99%
13 Jun
116.99
-1.14%
12 Jun
118.81
0.51%
11 Jun
112.47
4.39%
10 Jun
112.47
-0.14%
09 Jun
113.00
-0.96%
Alembic Limited Graph
Alembic Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Alembic Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 119.81, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 119.60 | 120.80 | 108.72 - 132.88 |
| 121.99 | 97.59 - 146.39 | ||
| 123.19 | 86.23 - 160.14 | ||
| Bearish Scenario | 119.60 | 118.40 | 106.56 - 130.24 |
| 117.21 | 93.77 - 140.65 | ||
| 116.01 | 81.21 - 150.82 |
Overview of Alembic Limited
ISIN
INE426A01027
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
758,930
Market Cap
30,657,202,861
Last Dividend
2.4
Official Website
IPO Date
2002-07-01
DCF Diff
187.26
DCF
-77
Financial Ratios Every Investor Needs
Stock Dividend of ALEMBICLTD
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-08-05 | August 05, 25 | 2.4 | 2.4 | 2025-08-05 | 2025-09-11 | |
| 2024-08-05 | August 05, 24 | 2.4 | 2.4 | 2024-08-05 | 2024-09-11 | |
| 2023-08-03 | August 03, 23 | 2.2 | 2.2 | 2023-08-03 | 2023-09-09 | |
| 2022-09-12 | September 12, 22 | 1.8 | 1.8 | 2022-09-13 | 2022-09-23 | |
| 2021-07-29 | July 29, 21 | 0.2 | 0.2 | 2021-07-30 | 2021-08-10 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 221.89 Cr | 69.16 Cr | 152.73 Cr | 0.6883 | 0.00 Cr | 0.00 Cr | 83.09 Cr | 310.68 Cr | 12.10 | 168.60 Cr | 1.4002 |
| 2024-03-31 | 147.12 Cr | 59.88 Cr | 87.25 Cr | 0.5930 | 0.10 Cr | 6.70 Cr | 49.02 Cr | 268.62 Cr | 10.46 | 105.50 Cr | 1.8258 |
| 2023-03-31 | 118.34 Cr | 48.13 Cr | 70.21 Cr | 0.5933 | 0.66 Cr | 5.51 Cr | 33.61 Cr | 190.65 Cr | 7.42 | 93.99 Cr | 1.6110 |
| 2022-03-31 | 71.37 Cr | 30.92 Cr | 40.45 Cr | 0.5668 | 1.03 Cr | 6.36 Cr | 9.07 Cr | 222.06 Cr | 8.65 | 103.11 Cr | 3.1114 |
| 2021-03-31 | 67.84 Cr | 28.56 Cr | 39.27 Cr | 0.5789 | 0.39 Cr | 3.64 Cr | 9.65 Cr | 342.84 Cr | 13.35 | 21.34 Cr | 5.0539 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 2.71 Cr | 2,503.00 Cr | 164.41 Cr | 2,338.5900 Cr | 14.45 Cr | 11.74 Cr | 99.39 Cr | 135.33 Cr | 0.00 Cr | 0.00 Cr | 1,844.95 Cr | 110.4700 Cr |
| 2024-03-31 | 1.26 Cr | 2,328.77 Cr | 143.21 Cr | 2,185.5645 Cr | 9.15 Cr | 7.89 Cr | 92.60 Cr | 131.64 Cr | 0.00 Cr | 0.00 Cr | 1,774.71 Cr | 90.3159 Cr |
| 2023-03-31 | 0.93 Cr | 2,204.58 Cr | 126.55 Cr | 2,078.0328 Cr | 0.00 Cr | -0.93 Cr | 88.61 Cr | 131.96 Cr | 0.00 Cr | 1.81 Cr | 1,662.72 Cr | 83.8105 Cr |
| 2022-03-31 | 1.17 Cr | 2,631.95 Cr | 135.37 Cr | 2,496.5833 Cr | 0.00 Cr | -1.17 Cr | 86.87 Cr | 133.69 Cr | 0.00 Cr | 2.02 Cr | 2,349.90 Cr | 67.7648 Cr |
| 2021-03-31 | 5.89 Cr | 2,408.96 Cr | 111.93 Cr | 2,297.0281 Cr | 0.28 Cr | -5.61 Cr | 54.28 Cr | 139.53 Cr | 0.00 Cr | 1.94 Cr | 2,166.44 Cr | 59.4153 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 86.3700 Cr | -26.5800 Cr | -58.3400 Cr | 35.6000 Cr | 1.4500 Cr | 2.7100 Cr | -50.7700 Cr | 155.5000 Cr | 5.3000 Cr | -61.1700 Cr | -6.7800 Cr |
| 2024-03-31 | 22.6865 Cr | 25.8363 Cr | -48.1936 Cr | -33.6034 Cr | 0.3291 Cr | 1.2609 Cr | -56.2899 Cr | 102.6862 Cr | 9.1490 Cr | -56.2340 Cr | -3.9900 Cr |
| 2023-03-31 | 38.8525 Cr | 7.2960 Cr | -46.3882 Cr | 13.0346 Cr | -0.2396 Cr | 0.9318 Cr | -25.8179 Cr | 86.8000 Cr | 0.0000 Cr | -45.9228 Cr | -1.7400 Cr |
| 2022-03-31 | -17.7469 Cr | 18.8478 Cr | -5.8165 Cr | -53.5601 Cr | -4.7157 Cr | 1.1714 Cr | -35.8132 Cr | 97.8574 Cr | -0.2766 Cr | -5.1508 Cr | -32.5884 Cr |
| 2021-03-31 | -2.1817 Cr | -34.8694 Cr | -15.3620 Cr | -49.6370 Cr | -52.9679 Cr | 5.8871 Cr | -47.4553 Cr | 17.0412 Cr | 0.2766 Cr | -15.2767 Cr | -18.8683 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 60.27 Cr | 17.38 Cr | 42.89 Cr | 0.7116 | 24.57 Cr | 68.45 Cr | 2.67 | 30.29 Cr | 1.1357 |
| 2024-12-31 | 57.92 Cr | 17.00 Cr | 40.92 Cr | 0.7065 | 23.70 Cr | 65.39 Cr | 2.55 | 30.76 Cr | 1.1290 |
| 2024-09-30 | 52.91 Cr | 18.71 Cr | 34.20 Cr | 0.6464 | 16.90 Cr | 121.02 Cr | 4.71 | 85.18 Cr | 2.2873 |
| 2024-06-30 | 50.78 Cr | 16.08 Cr | 34.70 Cr | 0.6833 | 26.97 Cr | 55.82 Cr | 2.17 | 22.36 Cr | 1.0993 |
| 2024-03-31 | 49.04 Cr | 18.98 Cr | 30.06 Cr | 0.6130 | 22.67 Cr | 72.15 Cr | 2.81 | 26.19 Cr | 1.4712 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 2.71 Cr | 59.95 Cr | 62.66 Cr | 29.97 Cr | 99.39 Cr | 204.87 Cr | 135.33 Cr | 2,503.00 Cr | 164.41 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 42.77 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -2,246.43 Cr |
| 2024-09-30 | 1.75 Cr | 44.01 Cr | 45.76 Cr | 43.46 Cr | 97.05 Cr | 199.72 Cr | 131.37 Cr | 2,440.96 Cr | 194.53 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 12.86 Cr | 0.00 Cr | 0.00 Cr | 12.86 Cr | 0.00 Cr | 0.00 Cr | -2,185.56 Cr |
| 2024-03-31 | 1.26 Cr | 11.64 Cr | 12.91 Cr | 21.90 Cr | 92.60 Cr | 137.39 Cr | 131.64 Cr | 2,328.77 Cr | 143.21 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 68.45 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 65.39 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 121.02 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 55.82 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 72.15 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2013-09-27 | September 27, 13 | 2:1 |
| 2006-09-26 | September 26, 06 | 5:1 |
| 2004-03-25 | March 25, 04 | 2:1 |
| 2003-12-10 | December 10, 03 | 1083:1000 |
| 1999-07-26 | July 26, 99 | 10:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,676.30 | ₹4,021,913,064,000.00 | ₹1,264,309.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,906.50 | ₹1,833,461,648,500.00 | ₹243,492.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,368.00 | ₹1,139,882,760,000.00 | ₹423,420.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,307.40 | ₹1,087,861,052,076.00 | ₹1,465,957.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹1,001.00 | ₹1,007,236,230,000.00 | ₹845,770.00 |
| Mankind Pharma Limited | MANKIND | ₹2,439.50 | ₹1,006,851,810,020.00 | ₹1,061,792.00 |
| Lupin Limited | LUPIN | ₹1,980.90 | ₹904,708,724,400.00 | ₹934,890.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,191.30 | ₹691,909,422,600.00 | ₹1,932,712.00 |
| Alkem Laboratories Limited | ALKEM | ₹4,886.30 | ₹584,230,459,500.00 | ₹94,011.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,830.40 | ₹516,540,710,400.00 | ₹814,804.00 |
| Laurus Labs Limited | LAURUSLABS | ₹776.00 | ₹418,460,328,000.00 | ₹3,229,261.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Cohance Lifesciences Limited | COHANCE | ₹1,036.50 | ₹396,530,703,792.00 | ₹477,093.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,422.80 | ₹360,970,051,200.00 | ₹104,198.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,695.50 | ₹336,700,296,000.00 | ₹240,554.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,724.80 | ₹280,243,779,200.00 | ₹593,242.00 |
| Piramal Enterprises Limited | PEL | ₹1,157.90 | ₹262,470,456,200.00 | ₹228,670.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,638.10 | ₹255,640,247,900.00 | ₹1,117,616.00 |
| Eris Lifesciences Limited | ERIS | ₹1,706.70 | ₹232,447,419,900.00 | ₹82,405.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,102.50 | ₹227,562,500,000.00 | ₹25,217.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹1,000.70 | ₹196,700,594,100.00 | ₹108,238.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,194.00 | ₹190,181,514,000.00 | ₹169,808.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹998.60 | ₹178,859,246,000.00 | ₹2,563,716.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹11,999.00 | ₹153,945,970,100.00 | ₹67,446.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,017.80 | ₹153,376,408,260.00 | ₹53,259.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹492.60 | ₹119,526,434,400.00 | ₹485,534.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,756.50 | ₹95,554,446,100.00 | ₹4,608.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹896.95 | ₹87,713,547,755.00 | ₹52,952.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹900.35 | ₹81,602,880,117.00 | ₹170,970.00 |
| Strides Pharma Science Limited | STAR | ₹885.25 | ₹81,587,030,175.00 | ₹352,026.00 |
| FDC Limited | FDC | ₹489.40 | ₹79,679,214,000.00 | ₹87,175.00 |
| Suven Life Sciences Limited | SUVEN | ₹255.11 | ₹55,632,858,140.00 | ₹130,167.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹158.84 | ₹51,547,074,480.00 | ₹224,206.00 |
| Innova Captab Limited | INNOVACAP | ₹859.60 | ₹49,190,549,828.00 | ₹73,430.00 |
| Sequent Scientific Limited | SEQUENT | ₹188.38 | ₹47,152,455,900.00 | ₹383,606.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹487.45 | ₹44,489,561,500.00 | ₹600,794.00 |
| Hikal Limited | HIKAL | ₹345.45 | ₹42,594,330,450.00 | ₹175,436.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹595.90 | ₹41,954,816,220.00 | ₹151,277.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,519.90 | ₹41,676,626,100.00 | ₹14,147.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹756.05 | ₹38,346,175,555.00 | ₹163,077.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹65.36 | ₹35,814,273,440.00 | ₹9,451,665.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹345.55 | ₹34,651,062,900.00 | ₹54,139.00 |
| Indoco Remedies Limited | INDOCO | ₹338.65 | ₹31,239,751,335.00 | ₹82,016.00 |
| Alembic Limited | ALEMBICLTD | ₹119.81 | ₹30,765,051,300.00 | ₹372,813.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹636.80 | ₹30,663,830,400.00 | ₹93,068.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹93.64 | ₹27,485,868,280.00 | ₹1,242,447.00 |
Key Executives
Company Secretary & Compliance Officer
Mr. Kevalkumar Bharatkumar Thakkar
Gender: male
Year Born:
MD, Chief Executive Officer & Executive Director
Ms. Malika Chirayu Amin
Gender: female
Year Born: 1955
President of Real Estate Operations
Mr. Avaneesh Nath Sharma
Gender: male
Year Born:
Chief Financial Officer
Mr. Rasesh Shah
Gender: male
Year Born:
Associate Vice President of HR
Mr. Ambarish Jambhorkar
Gender: male
Year Born:
FAQs about Alembic Limited
Who is the CEO of the company?
The CEO is Malika Chirayu Amin.
What is the current market price of the stock?
The current price is ₹119.39.
What is the 52-week price range?
The range is ₹85.46-169.
What is the market capitalization of the company?
The market capitalization is ₹3,065.72 crores.
What is the dividend yield?
The dividend yield is 2.01%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 9.86.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Alembic Limited (ISIN: INE426A01027) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹3,065.72 crores and an average daily volume of 758,930 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹2.4.